CRWV arrives at its June 8 earnings call in a materially different position than just 72 hours ago — the stock has fallen 7% on Friday alone, is down 21% over the past month, and the short covering story that defined last week's narrative has reversed sharply.
The price action is the headline. CRWV closed at $100.39, having shed more than a fifth of its value over the past month. Peers have also weakened — APLD dropped 11% on the week and WYFI fell nearly 15% — but CRWV's drawdown is deeper, suggesting company-specific pressure rather than pure sector rotation. Short interest has re-accelerated to match: SI climbed 8.8% in a single session to reach 14.3% of the free float, up 10.7% on the week. That reversal ends the covering trend flagged in earlier notes. The borrow market, however, is not flashing squeeze pressure. Cost to borrow remains negligible at 0.46%, and availability is ample at 567% of estimated short interest — meaning there are roughly five shares available to borrow for every one currently shorted. Shorts can add to positions cheaply and without friction.
Options positioning has shifted since the June 3 note, which flagged a deeply bullish put/call ratio of 0.72. The PCR has drifted back up to 0.81, almost exactly in line with its 20-day average. That is not a bearish signal, but the sharp call premium of two days ago has normalised. The setup no longer reads as decisively optimistic from an options standpoint — it reads as neutral, which in the context of a 7% down day and rising short interest is arguably a deterioration.
The insider activity adds an uncomfortable layer. CEO Michael Intrator sold roughly 145,000 shares across multiple tranches on June 2, realising close to $20 million at prices between $119 and $128 — well above where the stock trades today at $100. The sales follow a period of heavy insider selling across the cap table: co-founders Brian Venturo and Brannin McBee reduced positions by 6.9 million and roughly 1 million shares respectively in recent weeks. Insider net activity over 90 days is a small positive in share terms, but that reflects earlier accumulation; the most recent disclosed activity is uniformly in one direction. Magnetar Capital, the 10% owner, also sold a nominal position on June 2.
Analyst opinion remains broadly constructive but divided on valuation. BNP Paribas initiated at Outperform with a $192 target as recently as June 2 — a 91% premium to current levels that frames the bull case around long-term AI infrastructure demand and CoreWeave's operational moat. Citigroup raised its target to $158, and Cantor and Wells Fargo both lifted targets above $150. The bear case, articulated clearly by DA Davidson's downgrade to Neutral with a $100 target, centres on margin erosion: rising input costs, multi-year contracts without memory price hedging, and softer near-term guidance on average order intensity. JPMorgan sits at Neutral with a $105 target, essentially flat to current price, suggesting limited near-term conviction even among non-bears.
The one historical data point worth noting: at CRWV's last print on May 7, the stock fell 17% on the day and was still down 17% five sessions later. That was a first full-quarter earnings release for a recently public company, with market expectations not yet calibrated. The June 8 print is therefore a test of whether the company can address those same profitability concerns — margin trajectory, contract structure, and capital intensity — with enough conviction to stop the short base from rebuilding further.
See the live data behind this article on ORTEX.
Open CRWV on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
